Shares of Alterity Therapeutics ATHE were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for ...

STOCKHOLM, May 8, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that regulatory authorities in Spain in Poland have approved the inclusion of Multiple System ...

In the future there might be more time for students to study for finals. On Tuesday, the Minnesota Student Association passed a resolution to lobby the University administration and the Board of ...

At last night’s Michigan Student Assembly meeting, MSA representatives introduced three new resolutions and addressed six resolutions that were proposed at previous meetings. One of the proposals was ...

The clinical diagnosis of progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) remains challenging due to heterogeneity of the diseases. The final antemortem diagnosis was incorrect ...

Multiple system atrophy (MSA) is often difficult to distinguish from Parkinson's disease (PD) with autonomic failure, but this is an important distinction for research studies as well as for clinical ...

The goal is to develop a disease modifying treatment that stops or slow down the progression of alpha-synucleinopathies e.g. Parkinson's disease and MSA. BioArctic's phase 2a study EXIST with ...

Shares of Alterity Therapeutics (NASDAQ:ATHE) were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 ...